Our study indicates that BMP6/HAMP pathway insufficiency is associated with a worsen survival outcome in HCC patients and that hepcidin supplementation might improve patient outcome, but a further interventional study is needed to draw a clear conclusion. This evidence concerns the gene BMP6 and hepatocellular carcinoma.